Former US FDA Commissioner on Light Sciences Oncology board
This article was originally published in Clinica
Light Sciences Oncology (Washington, US), a company that has developed a light-activated device to enable drug treatment for solid tumours among other conditions, has appointed former US FDA Commissioner Frank Young to its board of directors – a newly created seat. Dr Young, whose internship and residency was in pathology, is currently a partner at Essex Woodlands Health Ventures, which is an investor in the company. Other senior positions held by Dr Young include US Representative to the executive committee of the World Health Organization, and dean of the school of medicine and dentistry and vice-president of health affairs at the University of Rochester in New York.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.